Granulomatous eruption after BCG vaccine immunotherapy for malignant melanoma

Shea, Christopher R.; Imber, Michael J.; Cropley, Thomas G.; Cosimi, A. Benedict; Sober, Arthur J.

doi:10.1016/s0190-9622(89)70310-8

Cited by 18 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These steroid treatment but the erythema persisted on the knees for consist mainly of contact dermatitis (3-6) and photocontact the next 10 days. Histologic examination of a skin lesion dermatitis (7-9), which may be persistent (10 ). We present showed a moderately acanthotic epidermis.…”

Section: Sirmentioning

confidence: 52%

“…Granulomatous reactions have been reported in cases of malignant melanoma (10)(11)(12) and other neoplasms (13) after BCG vaccine therapy, and during the course of Kawasaki disease (14). It has been postulated that molecule or molecules that are cross-reactive between suspected infectious agents and the mycobacterial BCG antigens may contribute to this in ammatory process (15).…”

Section: Sirmentioning

confidence: 99%

See 1 more Smart Citation

Delayed Granulomatous Lesion at the Bacillus Calmette-Gue´rin Vaccination Site

Gasior-Chrzan¹

2001

Acta Dermato-Venereologica

View full text Add to dashboard Cite

baseline warts (imiquimod 11% vs. vehicle 6%; p = 0.488), Douglas JM Jr. Treatment of genital warts with an immunemore imiquimod-treated patients experienced a 50% reducresponse modi er (imiquimod). J Am Acad Dermatol 1998; 32: tion in baseline wart area (38% vs. 14%; p = 0.013). Use of 230-239. imiquimod was not associated with any changes in laboratory 3. Beutner KR, Tyring SK, Trofatter KF, Douglas JM, Spruance S, values, including CD4 count. It was not associated with any Owens ML, et al. Imiquimod, a patient-applied immune-response adverse drug-related events, and no exacerbation of HIV/AIDS modi er for treatment of external genital warts. Antimicrob Agents was attributed to the use of imiquimod. However, it appeared

show abstract

Section: Sirmentioning

confidence: 52%

Section: Sirmentioning

confidence: 99%

Delayed Granulomatous Lesion at the Bacillus Calmette-Gue´rin Vaccination Site

Gasior-Chrzan¹

2001

Acta Dermato-Venereologica

View full text Add to dashboard Cite

show abstract

“…Rarely, severe hypotension and signs of disseminated intravascular coagulation were observed, suggesting the release of endotoxin from endogenous sources, such as the intestinal tract during a period of hypotension following an allergic reaction [100]. One patient showed multiple tuberculoid granulomas within papillary and reticular dermis, but without any evidence of mycobacteria [101].…”

Section: Side Effects Of Il-bcgmentioning

confidence: 99%

Clinical and molecular insights into BCG immunotherapy for melanoma

2020

View full text Add to dashboard Cite

The incidence of cutaneous melanoma and the mortality rate of advanced melanoma patients continue to rise globally. Despite the recent success of immunotherapy including ipilimumab and pembrolizumab checkpoint inhibitors, a large proportion of patients are refractory to such treatment modalities. The application of mycobacteria such as Bacillus Calmette–Guérin (BCG) in the treatment of various malignancies, including cutaneous melanoma, has been clearly demonstrated after almost a century of observations and experimentation. Intralesional BCG (IL‐BCG) immunotherapy is a highly efficient and cost‐effective treatment option for inoperable stage III in‐transit melanoma, as recommended in the National Comprehensive Cancer Network Guidelines. IL‐BCG has shown great efficacy in the regression of directly injected metastatic melanoma lesions, as well as distal noninjected nodules in immunocompetent patients. Clinical and preclinical studies have shown that BCG serves as a strong immune modulator, inducing the recruitment of various immune cells that contribute to antitumour immunity. However, the specific mechanism of BCG‐mediated tumour immunity remains poorly understood. Comparative genome analyses have revealed that different BCG strains exhibit distinct immunological activity and virulence, which might impact the therapeutic response and clinical outcome of patients. In this review, we discuss the immunostimulatory potential of different BCG substrains and highlight clinical studies utilizing BCG immunotherapy for the treatment of cutaneous melanoma. Furthermore, the review focuses on the cellular and molecular mechanisms of the BCG‐induced immune responses of both the innate and adaptive arms of the immune system. Furthermore, the review discussed the administration of BCG as a monotherapy or in combination with other immunotherapeutic or chemotherapeutic agents.

show abstract

“…Localized tuberculid in the form of LS has been described as an unusual complication of BCG vaccination given by multipuncture technique (2). Further, Shea et al (6) reported a similar case of granulomatous eruption confined to the right leg and thigh in a patient of malignant melanoma after BCG vaccine immunotherapy.…”

Section: Discussionmentioning

confidence: 96%

Genital Tuberculid in a Female Child: A New Entity (Childhood Vulval Tuberculid)

Pandhi¹,

Mehta²,

Singal³

2007

Pediatric Dermatology

View full text Add to dashboard Cite

Localized tuberculid has been infrequently reported in the literature. Most of these reports are of papulonecrotic tuberculids localized to the penis, an entity designated as "penis tuberculid." In females, such a localized genital tuberculid has not been documented till date. We report an 11-year-old girl with lichen scrofulosorum confined to the vulva, associated with cervical and inguinal tubercular lymphandenitis.

show abstract

Granulomatous eruption after BCG vaccine immunotherapy for malignant melanoma

Cited by 18 publications

References 11 publications

Delayed Granulomatous Lesion at the Bacillus Calmette-Gue´rin Vaccination Site

Delayed Granulomatous Lesion at the Bacillus Calmette-Gue´rin Vaccination Site

Clinical and molecular insights into BCG immunotherapy for melanoma

Genital Tuberculid in a Female Child: A New Entity (Childhood Vulval Tuberculid)

Contact Info

Product

Resources

About